| Previous Close | 33.48 |
| Open | 33.38 |
| Bid | 33.35 x 600 |
| Ask | 33.42 x 200 |
| Day's Range | 33.17 - 33.44 |
| 52 Week Range | 29.83 - 37.39 |
| Volume | 14,761,637 |
| Avg. Volume | 20,427,780 |
| Market Cap | 198.85B |
| Beta | 1.07 |
| PE Ratio (TTM) | 28.05 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Dividend & Yield | 1.28 (3.82%) |
| Ex-Dividend Date | 2017-08-02 |
| 1y Target Est | N/A |
- Market Realist•2 hours ago
Why Ibrance Could Be Pfizer’s Long-Term Growth Driver
Pfizer (PFE) is extensively conducting clinical trials for the label expansion of Ibrance.
- Market Realist•4 hours ago
Why Ibrance Could Drive Pfizer’s Revenue Growth
In 2016, Pfizer’s (PFE) Ibrance reported revenues of ~$2.1 billion, compared with $723 million in 2015.
Bloomberg•5 hours agoMerck, Samsung Accelerate a Biosimilar Price War
The days of high-priced knockoffs of biologic drugs are ending quickly.
